Azzalure botulic toxin wins EU approval

Published: 3-Feb-2009

French independent pharma group Ipsen has received collective marketing approval from 15 EU member states to market its botulic toxin Azzalure to treat facial wrinkling.


French independent pharma group Ipsen has received collective marketing approval from 15 EU member states to market its botulic toxin Azzalure to treat facial wrinkling.

Ipsen sold development and distribution rights in the EU for the aesthetic
 indications of its botulic toxin in
2007 to the Nestle-L'Oréal joint venture Galderma. The toxin was originally 
developed by Allergan of the US 
as Botox as a treatment for muscular spasm. Ipsen has said it hopes to
 receive US marketing approval in 
mid-2009.

You may also like